▴ Trovafloxacin is a fluoroquinolone antibacterial agent with a broad spectrum of activity.
▴ Trovafloxacin has similar or 2-fold lower activity than ciprofloxacin against Enterobacteriaceae and Pseudomonas aeruginosa. Against Haemophilus influenzae and Moraxella catarrhalis, trovafloxacin has similar activity to ciprofloxacin. Other susceptible Gram-negative pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis and mycoplasmas.
▴ The drug is active against Gram-positive bacteria and consistently displayed greater activity (2- to 8-fold) than ciprofloxacin against all staphylococci and streptococci tested; activity included methicillin-resistant staphylococci and penicillin-resistant Streptococcus pneumoniae. Trovafloxacin has some activity against vancomycin-resistant enterococci.
▴ Anaerobes such as Bacteroides and Clostridium spp. are also susceptible to trovafloxacin.
▴ Preliminary clinical data suggest that trovafloxacin is effective in the treatment of patients with upper and lower respiratory tract and uncomplicated urinary tract infections and infections caused by C. trachomatis or N. gonorrhoeae.
▴ The most frequently noted adverse event with trovafloxacin is dizziness which is reported in 11% of patients versus 3% of those receiving comparator agents. Other commonly reported events (>1% of patients) are nausea, headache, vomiting, vaginitis and diarrhoea.
KeywordsOfloxacin Antimicrob Agent Chlamydia Trachomatis Eradication Rate Vitro Activity
Unable to display preview. Download preview PDF.
- 1.Brighty KE, Gootz TD, Girard A, et al. Prodrugs of CP-99,219 for intravenous administration; synthesis and evaluation resulting in identification of CP-116,517 [abstract no. 730]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26–30; Vienna, 141Google Scholar
- 9.Roblin PM, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae [abstract no. 2244]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 28Google Scholar
- 11.Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996 Feb; 40(2): 314–9PubMedGoogle Scholar
- 12.Girard AE, Cimochowski CR, Girard D, et al. In vitro and in vivo activities of CP-99,219 against Helicobacter [abstract no. F24]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994; 1994 Oct 4–7; Orlando, 55Google Scholar
- 16.Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995 Jan; 35: 230–2PubMedCrossRefGoogle Scholar
- 27.Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 1997 Jun; 39: 797–802PubMedCrossRefGoogle Scholar
- 31.Teng R, Dogolo LC, Willavize SA, et al. Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volunteers [abstract no. F238]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 154Google Scholar
- 36.Teng R, Dogolo LC, Willavize S, et al. Effect of sucralfate, calcium carbonate and ferrous sulphate on the bioavailability of trovafloxacin [abstract no. 71.007]. 7th International Congress for Infectious Diseases; 1996 Jun 10–13; Hong Kong, 186Google Scholar
- 39.Patterson BE, Pukins L, Oliver SJ, et al. An open, placebo-controlled, two-way crossover study to investigate the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin [abstract no. 71.019]. 7th International Congress for Infectious Diseases; 1996 Jun 10–13; Hong Kong, 188Google Scholar
- 40.Teng R, Apseloff G, Vincent J, et al. Effect of trovafloxacin (CP-99,219) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects [abstract no. A2]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 1Google Scholar
- 41.Patterson BE, Kleinermans D, Brown SJ, et al. Effects of orally administered trovafloxacin on the steady-state pharmacokinetics of digoxin: results of a double-blind, placebo-controlled, parallel-group study [abstract no. 70.022]. 7th International Congress for Infectious Diseases; 1996 Jun 10–13; Hong KongGoogle Scholar
- 42.Fiddes R, Syndor A, Johnson P, et al. The efficacy and safety of trovafloxacin in the treatment of acute bacterial sinusitis [abstract no. 2263]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 32Google Scholar
- 44.Anonymous. Pfizer highlighting ziprasidone lower weight gain in schizophrenics compared to Lilly Zyprexa; trovafloxacin NDA filing for 12 indications set for December. FDC Pink November: 12Google Scholar
- 46.Martin DH, Jones RB, Johnson RB. A phase II study of CP-99,219-27 for the treatment of Chlamydia trachomatis infections [abstract no. LM33]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 332Google Scholar
- 47.Pfizer Inc. Data on fileGoogle Scholar
- 48.Ferguson J, Patterson BE, Purkins L, et al. An open, observerblinded, placebo-controlled, randomized, parallel-group study to investigate the phototoxic potential of trovafloxacin, ciprofloxacin and lomefloxacin [abstract no. A15]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 15–18 Sep; New OrleansGoogle Scholar